You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. RAIN ONCOLOGY INC

Rain Oncology Inc XNAS: RAIN

Rain Oncology Inc Live Share Price Today, Share Analysis and Chart

Download real time

2.50 0.06 (2.46%)

74.83% Gain from 52W Low

6,317 XNAS Volume

High volume today

XNAS 21 Apr, 2025 11:08 AM (EDT)

Watchlist

Portfolio

Share
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
0.5 / 100
Momentum Score
Technically Bullish
75.2 / 100
Analyst Price Target
No estimates available

22

S

5

W

1

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Rain Oncology Inc Live Price Chart

Switch to TradingView
Created with Highcharts 9.0.1Chart context menu24. Feb3. Mar10. Mar17. Mar24. Mar31. Mar7. Apr14. Apr21. AprMay '21Sep '21Jan '22May '22Sep '22Jan '23May '23Sep '23Jan '25123408kZoom1D1W1M3M1Y5YAllApr 21, 2024→Apr 21, 2025trendlyne.com

Rain Oncology Inc Stock Analysis

Rain Oncology Inc stock analysis with key metrics, changes, and trends.

Rain Oncology Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$75.72 M47.34%negative

Annual Net Profit fell 47.34% in the last year to $75.72 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio-1.26-negative

Price to Earning Ratio is -1.26, which is negative.

Stock Price$2.50106.61%positive

Stock Price rose 106.61% and outperformed its sector by 99.25% in the past year.

Quarterly Net profit$7.03 M61.01%positive

Quarterly Net profit rose 61.01% YoY to $7.03 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Mutual Fund Holding12.01 %-1.29%negative

Mutual Fund Holding decreased by 1.29% in the last quarter to 12.01.

Institutional Holding43.37 %0%neutral

Institutional Holding remained the same in the last quarter at 43.37%.

VIEW LESS


Loading data..

Rain Oncology Inc - Company Profile

Rain Oncology Inc Management structure

All Gross Remunerations are in USD
Mr. Avanish Vellanki
Chairman of the Board and Chief Executive Officer
2.19 M
2022
Gross Remuneration
Year
Dr. Robert Doebele, M.D.
President and Chief Scientific Officer
1.43 M
2022
Gross Remuneration
Year
Dr. Richard P. Bryce
Executive Vice President and Chief Medical Officer
1.21 M
2022
Gross Remuneration
Year
Mr. Nelson Cabatuan
Senior Vice President, Finance and Operations, Principal Financial & Accounting officer
-
2022
Gross Remuneration
Year
Mr. Erik Atkisson
General Counsel and Chief Compliance Officer
-
2022
Gross Remuneration
Year

Rain Oncology Inc Board of directors

All Gross Remunerations are in USD
Mr. Franklin M. Berger, C.F.A.
Lead Independent Director
117.75 K
2022
Gross Remuneration
Year
Mr. Tran B. Nguyen
Independent Director
94.25 K
2022
Gross Remuneration
Year
Mr. Peter Radovich
Independent Director
89.25 K
2022
Gross Remuneration
Year
Ms. Stefani A. Wolff
Independent Director
83.25 K
2022
Gross Remuneration
Year
Mr. Aaron Davis
Independent Director
82.75 K
2022
Gross Remuneration
Year
Dr. Gorjan Hrustanovic, PhD
Independent Director
80.25 K
2022
Gross Remuneration
Year

Rain Oncology Inc FAQ

How is Rain Oncology Inc today?
Rain Oncology Inc today is trading in the green, and is up by 2.46% at 2.50.
Rain Oncology Inc is currently trading up 2.46% on an intraday basis. In the past week the stock rose 12.61%. stock has been up 106.61% in the past quarter and rose 106.61% in the past year. You can view this in the overview section.